177 related articles for article (PubMed ID: 30423844)
1. Biochemical and Anti-Triple Negative Metastatic Breast Tumor Cell Properties of Psammaplins.
Zhou YD; Li J; Du L; Mahdi F; Le TP; Chen WL; Swanson SM; Watabe K; Nagle DG
Mar Drugs; 2018 Nov; 16(11):. PubMed ID: 30423844
[TBL] [Abstract][Full Text] [Related]
2. Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
Cincinelli R; Musso L; Artali R; Guglielmi M; Bianchino E; Cardile F; Colelli F; Pisano C; Dallavalle S
Eur J Med Chem; 2018 Jan; 143():2005-2014. PubMed ID: 29150335
[TBL] [Abstract][Full Text] [Related]
3. Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase.
Piña IC; Gautschi JT; Wang GY; Sanders ML; Schmitz FJ; France D; Cornell-Kennon S; Sambucetti LC; Remiszewski SW; Perez LB; Bair KW; Crews P
J Org Chem; 2003 May; 68(10):3866-73. PubMed ID: 12737565
[TBL] [Abstract][Full Text] [Related]
4. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
Jiang XC; Tu FH; Wei LY; Wang BZ; Yuan H; Yuan JM; Rao Y; Huang SL; Li QJ; Ou TM; Wang HG; Tan JH; Chen SB; Huang ZS
J Med Chem; 2022 Sep; 65(18):12346-12366. PubMed ID: 36053318
[TBL] [Abstract][Full Text] [Related]
6. Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis.
Wawruszak A; Luszczki JJ; Kalafut J; Okla K; Halasa M; Rivero-Muller A; Stepulak A
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357442
[TBL] [Abstract][Full Text] [Related]
7. Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
Wu B; Fathi S; Mortley S; Mohiuddin M; Jang YC; Oyelere AK
Bioorg Med Chem; 2020 Mar; 28(6):115345. PubMed ID: 32061484
[TBL] [Abstract][Full Text] [Related]
8. Marine Actinomycetes as potential source for histone deacetylase inhibitors and epigenetic modulation.
Varghese TA; Jayasri MA; Suthindhiran K
Lett Appl Microbiol; 2015 Jul; 61(1):69-76. PubMed ID: 25880615
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
10. Bioassay for the identification of natural product-based activators of peroxisome proliferator-activated receptor-gamma (PPARgamma): the marine sponge metabolite psammaplin A activates PPARgamma and induces apoptosis in human breast tumor cells.
Mora FD; Jones DK; Desai PV; Patny A; Avery MA; Feller DR; Smillie T; Zhou YD; Nagle DG
J Nat Prod; 2006 Apr; 69(4):547-52. PubMed ID: 16643023
[TBL] [Abstract][Full Text] [Related]
11. [Inhibition of Histone Deacetylases Reverses Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer Cells through a Slug Mediated Mechanism].
Rahimian A; Barati G; Mehrandish R; Mellati AA
Mol Biol (Mosk); 2018; 52(3):474-481. PubMed ID: 29989579
[TBL] [Abstract][Full Text] [Related]
12. Targeting breast cancer stem cells by novel HDAC3-selective inhibitors.
Hsieh HY; Chuang HC; Shen FH; Detroja K; Hsin LW; Chen CS
Eur J Med Chem; 2017 Nov; 140():42-51. PubMed ID: 28923385
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of hypoxia-related responses by novel antitumor histone deacetylase inhibitors in MDAMB231 breast cancer cells.
Naldini A; Filippi I; Cini E; Rodriquez M; Carraro F; Taddei M
Anticancer Agents Med Chem; 2012 May; 12(4):407-13. PubMed ID: 22043993
[TBL] [Abstract][Full Text] [Related]
14. Diallyl trisulfides, a natural histone deacetylase inhibitor, attenuate HIF-1α synthesis, and decreases breast cancer metastasis.
Wei Z; Shan Y; Tao L; Liu Y; Zhu Z; Liu Z; Wu Y; Chen W; Wang A; Lu Y
Mol Carcinog; 2017 Oct; 56(10):2317-2331. PubMed ID: 28574600
[TBL] [Abstract][Full Text] [Related]
15. Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.
Wen J; Bao Y; Niu Q; Yang J; Fan Y; Li J; Jing Y; Zhao L; Liu D
Eur J Med Chem; 2016 Feb; 109():350-9. PubMed ID: 26814680
[TBL] [Abstract][Full Text] [Related]
16. Highly ligand efficient and selective N-2-(Thioethyl)picolinamide histone deacetylase inhibitors inspired by the natural product psammaplin A.
Baud MG; Haus P; Leiser T; Meyer-Almes FJ; Fuchter MJ
ChemMedChem; 2013 Jan; 8(1):149-56. PubMed ID: 23184734
[TBL] [Abstract][Full Text] [Related]
17. The Application of Non-Invasive Apoptosis Detection Sensor (NIADS) on Histone Deacetylation Inhibitor (HDACi)-Induced Breast Cancer Cell Death.
Hsu KW; Huang CY; Tam KW; Lin CY; Huang LC; Lin CL; Hsieh WS; Chi WM; Chang YJ; Wei PL; Chen ST; Lee CH
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393914
[TBL] [Abstract][Full Text] [Related]
18. HDAC inhibitors induce proline dehydrogenase (POX) transcription and anti-apoptotic autophagy in triple negative breast cancer.
Fang H; Du G; Wu Q; Liu R; Chen C; Feng J
Acta Biochim Biophys Sin (Shanghai); 2019 Sep; 51(10):1064-1070. PubMed ID: 31559416
[TBL] [Abstract][Full Text] [Related]
19. The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
Ono H; Sowa Y; Horinaka M; Iizumi Y; Watanabe M; Morita M; Nishimoto E; Taguchi T; Sakai T
Breast Cancer Res Treat; 2018 Aug; 171(1):43-52. PubMed ID: 29752686
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic regulation of miR-200 as the potential strategy for the therapy against triple-negative breast cancer.
Mekala JR; Naushad SM; Ponnusamy L; Arivazhagan G; Sakthiprasad V; Pal-Bhadra M
Gene; 2018 Jan; 641():248-258. PubMed ID: 29038000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
